LYEL vs AIRJW Comparison

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

AirJoule Technologies Corp is an advance technology company whose purpose is to free the world from its water and energy constraints by delivering groundbreaking sorption technologies. The company platform technology, AirJoule, produces pure distilled water from air and, at commercial scale, will mitigate water scarcity through distributed water generation for businesses and consumers around the world. Its products are especially valuable for industrial users, which generate amounts of waste heat that can be used to power sorption technologies to produce low-cost pure distilled water and dehumidified air, two key inputs for a variety of industrial activities, including data centers and advance manufacturing. The Company operates as a single operating and reportable segment.